Hadasit Bio-Holdings Ltd (HSITF)
USD 0.12
(0.0%)
USD 0.12
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.57 Million ILS | -46.25% |
| 2022 | 2.93 Million ILS | 1443.16% |
| 2021 | 190 Thousand ILS | -94.04% |
| 2020 | 3.18 Million ILS | 1856.44% |
| 2019 | 163 Thousand ILS | 7.95% |
| 2018 | 151 Thousand ILS | -90.77% |
| 2017 | 1.63 Million ILS | -5.98% |
| 2016 | 1.74 Million ILS | 3.26% |
| 2015 | 1.68 Million ILS | -21.88% |
| 2014 | 2.15 Million ILS | -25.6% |
| 2013 | 2.89 Million ILS | 485.66% |
| 2012 | 495 Thousand ILS | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.69 Million ILS | 0.0% |
| 2024 Q1 | 1.69 Million ILS | 7.23% |
| 2023 Q1 | 3.2 Million ILS | 9.31% |
| 2023 Q4 | 1.57 Million ILS | 0.0% |
| 2023 FY | 1.57 Million ILS | -46.25% |
| 2023 Q3 | 1.57 Million ILS | -50.83% |
| 2023 Q2 | 3.2 Million ILS | 0.0% |
| 2022 Q2 | - ILS | 0.0% |
| 2022 FY | 2.93 Million ILS | 1443.16% |
| 2022 Q4 | 2.93 Million ILS | 0.0% |
| 2022 Q3 | 2.93 Million ILS | 0.0% |
| 2022 Q1 | - ILS | -100.0% |
| 2021 FY | 190 Thousand ILS | -94.04% |
| 2021 Q4 | 190 Thousand ILS | 0.0% |
| 2021 Q2 | - ILS | 0.0% |
| 2021 Q3 | 190 Thousand ILS | 0.0% |
| 2021 Q1 | - ILS | -100.0% |
| 2020 FY | 3.18 Million ILS | 1856.44% |
| 2020 Q2 | - ILS | 0.0% |
| 2020 Q3 | 3.18 Million ILS | 0.0% |
| 2020 Q4 | 3.18 Million ILS | 0.0% |
| 2020 Q1 | - ILS | -100.0% |
| 2019 Q3 | 163 Thousand ILS | 0.0% |
| 2019 Q4 | 163 Thousand ILS | 0.0% |
| 2019 Q1 | - ILS | -100.0% |
| 2019 FY | 163 Thousand ILS | 7.95% |
| 2019 Q2 | - ILS | 0.0% |
| 2018 Q1 | - ILS | -100.0% |
| 2018 FY | 151 Thousand ILS | -90.77% |
| 2018 Q3 | 151 Thousand ILS | 0.0% |
| 2018 Q2 | - ILS | 0.0% |
| 2018 Q4 | 151 Thousand ILS | 0.0% |
| 2017 FY | 1.63 Million ILS | -5.98% |
| 2017 Q1 | 1.34 Million ILS | -22.76% |
| 2017 Q2 | 1.34 Million ILS | 0.0% |
| 2017 Q3 | 1.36 Million ILS | 1.34% |
| 2017 Q4 | 1.63 Million ILS | 20.12% |
| 2016 Q4 | 1.74 Million ILS | 41.92% |
| 2016 FY | 1.74 Million ILS | 3.26% |
| 2016 Q3 | 1.22 Million ILS | 2.77% |
| 2016 Q2 | 1.19 Million ILS | 7.28% |
| 2016 Q1 | 1.11 Million ILS | -34.01% |
| 2015 Q1 | 1.28 Million ILS | -40.52% |
| 2015 Q4 | 1.68 Million ILS | 53.46% |
| 2015 Q2 | 980 Thousand ILS | -23.62% |
| 2015 Q3 | 1.09 Million ILS | 12.04% |
| 2015 FY | 1.68 Million ILS | -21.88% |
| 2014 FY | 2.15 Million ILS | -25.6% |
| 2014 Q3 | 1.82 Million ILS | 0.0% |
| 2014 Q2 | - ILS | -100.0% |
| 2014 Q1 | 151 Thousand ILS | -94.79% |
| 2014 Q4 | 2.15 Million ILS | 17.93% |
| 2013 Q1 | - ILS | -100.0% |
| 2013 Q4 | 2.89 Million ILS | 0.0% |
| 2013 Q3 | - ILS | 0.0% |
| 2013 FY | 2.89 Million ILS | 485.66% |
| 2013 Q2 | - ILS | 0.0% |
| 2012 Q4 | 495 Thousand ILS | 0.0% |
| 2012 FY | 495 Thousand ILS | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | 18.13% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 96.175% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -292.187% |
| SQZ Biotechnologies Company | 27.47 Million USD | 94.263% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 32.243% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 96.366% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 94.706% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -66.197% |
| Marizyme, Inc. | 18.71 Million USD | 91.58% |
| Genus plc | 233.1 Million USD | 99.324% |
| Pharming Group N.V. | 171.54 Million USD | 99.081% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -77.465% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -17.298% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -110.133% |
| ContraFect Corporation | 2.88 Million USD | 45.297% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -8.966% |
| IMV Inc. | 28.88 Million USD | 94.544% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 72.147% |
| ONE Bio Corp. | 19.71 Million USD | 92.006% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.259% |
| Mesoblast Limited | 118.7 Million USD | 98.672% |
| MultiCell Technologies, Inc. | 202.58 USD | -777864.261% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 95.239% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.623% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -150.128% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -28.301% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 61.766% |
| Biomind Labs Inc. | 735.54 Thousand USD | -114.264% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 47.921% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 87.874% |
| Skye Bioscience, Inc. | 4.61 Million USD | 65.852% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -338.131% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 46.219% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1013.639% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1063.211% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 73.157% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -6027.765% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -5.436% |
| Q BioMed Inc. | 4.1 Million USD | 61.654% |
| GB Sciences, Inc. | 1.75 Million USD | 10.419% |
| Alpha Cognition Inc. | 1.22 Million USD | -29.141% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Agentix Corp. | 50 Thousand USD | -3052.0% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.67% |
| Enzolytics Inc. | 996.33 Thousand USD | -58.179% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | 75.72% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -516.608% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 30.215% |
| argenx SE | 20 Million USD | 92.12% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 96.541% |
| HST Global, Inc. | 98.31 Thousand USD | -1502.946% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -533.644% |
| Halberd Corporation | 150 Thousand USD | -950.667% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 77.717% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -15313.203% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 41.817% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 34.271% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -587.336% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -960.18% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -685.58% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 28.36% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 92.247% |
| Kadimastem Ltd | 891.22 Thousand USD | -76.835% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 66.549% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -529.941% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -4589.639% |
| Cell Source, Inc. | 9.25 Million USD | 82.97% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -108.409% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -108.409% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -225.429% |
| Itoco Inc. | 228.37 Thousand USD | -590.087% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -647.008% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 68.372% |
| International Stem Cell Corporation | 4.17 Million USD | 62.279% |
| CytoDyn Inc. | 30.07 Million USD | 94.76% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -347.922% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 79.846% |
| SYBLEU INC | 477.5 Thousand USD | -230.052% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1186.531% |
| Rebus Holdings, Inc. | 310 Thousand USD | -408.387% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 66.718% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2425.115% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 27.736% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 81.049% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 81.642% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1.319% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -488.06% |
| Neutra Corp. | 54.15 Thousand USD | -2810.112% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 13.88% |
| PureTech Health plc | 25.51 Million USD | 93.823% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -28.734% |
| IXICO plc | 472.02 Thousand USD | -233.882% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 89.833% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.469% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Cellectis S.A. | 92.77 Million USD | 98.301% |